AEYE Health

"We finally have a solution for our retinopathy screening. It is the easiest system that we have worked with." Making a real difference in closing care gaps comes down to one thing: workflow fit. Adding the 1-minute diabetic eye exams right alongside routine vitals (weight, blood pressure, temperature), screening becomes a seamless addition instead of a clinical disruption. The outcome: "Substantial improvements in care gap closure." See how AEYE-DS makes screening effortless in the clip below.

Reactive care is expensive, but with AEYE-DS autonomous AI at the point of care, scalable prevention is not only economically sound, it is entirely possible and the right thing to do for patients and society.

For primary care practices, MIPS Quality ID #117 (Diabetes: Eye Exam) is often one of the most frustrating metrics to manage. Over 40 million Americans live with diabetes, and diabetic retinopathy remains the leading cause of blindness in working-age adults. While early detection can prevent at least 95% of vision loss, relying on external specialty referrals leaves major care gaps open: - Over 60% of patients miss their annual diabetic eye exams. - Staff waste dozens of hours chasing missing specialist reports. - Practices risk Medicare reimbursement penalties of up to -9%. There is a better way. CMS explicitly permits point-of-care autonomous AI under CPT code 92229 to satisfy MIPS #117 during routine wellness visits. Implementing AEYE-DS allows practices to deploy the 1-minute FDA-cleared, portable autonomous AI screening, closing the MIPS #117 care gap:   Image capture: Clinic staff capture a single image per eye without dilation. Instant AI Diagnosis: Results automatically populate in the EHR while the provider discusses findings directly with the patient, referring positive cases immediately. Automated Billing: The practice retains 100% of CPT 92229 reimbursement while satisfying MIPS #117. Point-of-care AI transforms MIPS #117 from a costly administrative headache into a streamlined, reimbursable clinical success that simultaneously boosts HEDIS scores, Star ratings, and ACO quality targets. Read our full guide to learn how PCPs are maximizing quality scores while protecting patient vision: https://lnkd.in/eAwqYz5u

More specialists, more clinics. For decades that was the only way to expand diagnostic access. But human expertise doesn't scale the way healthcare demand does. The infrastructure question hasn't changed. The answer to the problem has. Autonomous diagnostic AI with AEYE-DS removes the bottleneck entirely, making diabetic eye exams a part of every routine visit.

Once in a while, the funding and the technology line up perfectly. For rural health systems, that moment is now, with the $50B Rural Health Transformation Program. RHTP's $50B aims to modernize rural infrastructure and expand preventive care access. Diabetic retinopathy screening fits two of its approved categories cleanly: Chronic Disease Management and Technology Innovation. Nationally, more than 60% of patients with diabetes miss their annual eye exam, and in rural communities it's even worse. It's an access problem, driven by specialist shortages, long waits, and travel distance. That's exactly where point-of-care screening with autonomous AI changes the equation. AEYE-DS is an FDA-cleared, 1-minute autonomous AI screening for diabetic retinopathy that happens during a regular checkup. It's uniquely built for the point of care: the only fully autonomous AI screening cleared with a portable, handheld camera. Your staff run the screening, the AI delivers instant results, and documentation, billing, and reporting automate in your EHR. Results are discussed with the patient before they leave the room, so every patient can receive vision-saving screening. This is a rare, perfectly aligned strategic win. Grants can offset the subscription cost, while CPT 92229 reimbursement supports your quality measures and adds recurring revenue. The grant cound fund the technology. Reimbursement pays for every exam after that. Two separate things, so instead of competing, they compound. And it lifts your quality scores. Closing this care gap on-site strengthens your HEDIS Diabetic Eye Exam measure and MIPS Measure 117, keeps care inside your network, and maximizes your value-based care incentives. Using state funding to deploy cutting-edge AI isn't just innovative. It's the most sustainable way to protect patient sight while driving real bottom-line growth for rural health systems. One caveat: RHTP is a competitive, scored application through your state, not an entitlement. States back high-impact projects that plug into existing primary care workflows, so it's worth building a case with clear, measurable outcomes. We broke down how to do exactly that: positioning AI diagnostics against your state's targets, and improving your HEDIS and MIPS Measure 117 scores. 👇 Read our full guide here: https://lnkd.in/d_8-XXNE

Where a patient lives shouldn't dictate whether they receive care. AEYE-DS autonomous AI brings 1-minute diabetic eye screenings to patients wherever they are, closing the gap. And the RHTP grant can now help fund it.

The new $50B Rural Health Transformation Program (RHTP) can completely remove the funding barrier for rural clinics. Here’s a quick breakdown on how to use it to deploy FDA-cleared AI screenings at your clinic and close the diabetic eye care gap.

Over 60% of patients with diabetes skip their annual diabetic eye exam. In rural America, that gap is often even wider because the nearest retina specialist can be hours away, transforming a routine check-up into a full day off work. That’s where the $50B Rural Health Transformation Program (RHTP) comes in, helping you close that care gap. Several states are already directing this funding to chronic disease prevention and technology innovation, exactly where autonomous, point-of-care AI diagnostics can fit. Best of all, RHTP funding covers the setup and subscription rather than the clinical exam itself.  Individual screenings are billed separately under CPT code 92229, turning a grant-funded initiative into a self-funding revenue engine. One caveat: RHTP is a competitive, scored application through your state - not an entitlement. The states reward high-impact projects that plug into existing primary care workflows. Given that, it's worth building a case that shows clear, measurable impact. We broke down how to position AI diagnostics against your state's outcome targets, navigate the RFP process, and improve your HEDIS and MIPS Measure 117 scores. You can read the full analysis here: https://lnkd.in/d6cFB_Ga

A fantastic win for patient care! CMS is shifting the focus from box-checking to real clinical outcomes, and we are ready to help health plans deliver on that promise with point of care screening using AEYE-DS, FDA-cleared autonomous AI.

Teleretina sounded like a great promise for diabetic retinopathy (DR) screening. Take a few retinal images in a primary care clinic, upload them to the cloud, and let remote specialists read them. Clean, simple, and modern. Except it isn't. While teleretina solutions promised to close the care gap, health systems across the country are quietly abandoning these workflows. The reason? What works on paper collapses in a real clinic. Legacy teleretina creates administrative bottlenecks, delivers negative ROI, and fails far too often. The good news? Routing the same retinal image through AEYE-DS, FDA-cleared autonomous AI, changes everything, replacing a broken process with a 1-minute screening that closes the care gap right then, in-visit. Here is how AI is outpacing teleretina across the three metrics that matter most: speed, cost, and scale. Accuracy: Teleretina suffers from ungradeable images 30% of the time, forcing staff to chase patients down days later for re-tests. AI delivers instant, in-visit diagnosis with a >99% success rate, ensuring virtually all patients complete the screening in-visit. Speed: With teleretina, results take 24–72 hours, and a major study showed that only 20% of patients even knew they may need a follow-up with a specialist. AEYE-DS simplifies the entire process. It ensures all patients are screened in 1-minute and can discuss their results with their provider right then and there, in-visit. Cost & ROI: Instead of burning an hour of staff time chasing delayed results for a portion of the reimbursement (CPT 92250-TC), AEYE-DS turns screening into an effortless, 1-minute step during the visit. It automates charting and billing while unlocking a dedicated reimbursement code (CPT 92229) that maximizes your clinic's returns. The Bottom Line: Teleretina creates administrative burden, fails far too often, and introduces delays where critical recommendations are lost. AEYE-DS autonomous AI fixes this broken process by ensuring patients can be screened reliably, in-visit, closing the care gap on the spot while capturing higher reimbursement. Read the full breakdown here: https://lnkd.in/dhBvdudw